Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Autoimmune Diseases Common in Patients with Vitiligo

Will Boggs, MD  |  November 19, 2015

“Interestingly, vitiligo patients with a comorbid disease have a later age of onset and a longer duration of vitiligo,” Dr. Boniface says. “Care providers have to be aware of these comorbid diseases’ association with vitiligo in order to screen patients for autoimmune diseases, including thyroid disease, symptoms for systemic lupus erythematosus, and neurologic diseases when indicated.”

Dr. Yen-Ta Chen from Taipei Veterans General Hospital in Taiwan, who has done similar research, told Reuters Health by email, “In our study conducted in easterners, the most common associated disease is alopecia areata, not the thyroid disease in westerners. In their article, they conduct the stratification by race and also stated that white patients suffered from less alopecia areata than black patients. Therefore, the racial discrepancies between white and colored-skin patients do exist and further support the finding in our previous research.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Chen also supported screening patients with familial or extensive vitiligo for comorbid autoimmune diseases.

Page: 1 2 | Single Page
Share: 

Filed under:Conditions Tagged with:Autoimmune diseasecomorbiditiesskinvitiligo

Related Articles

    Causes of Alopecia Can Vary Among Patients with Systemic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting

    March 1, 2014

    Beyond such autoimmune diseases as systemic lupus erythematosus and rheumatoid arthritis, rheumatologists should consider hypothyroidism, dietary issues, and grooming habits in patients with hair loss

    New Research Points to Possible Future Treatment Option for Alopecia Areata

    October 24, 2014

    Topical application of protein tyrosine kinase inhibitors shown to reverse mouse model of the disease

    Tips for Treating Lupus-Related Renal Disease, Pain, Alopecia

    January 19, 2018

    SAN DIEGO—Rheumatologists who treat lupus patients gleaned tips on diagnosis and management of renal disease, painful neuropathies and alopecia at a “Curbside Consults” session held Nov. 6 at the ACR/ARHP Annual Meeting in San Diego. Membranous Lupus Nephritis Patients with refractory membranous lupus nephritis (MLN), or Class V lupus nephritis, face “significant morbidity, most of…

    Case Report: Tumor Treatment Unleashes Autoimmunity

    November 17, 2019

    Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) axes have revolutionized therapy and improved survival in advanced cancers. However, these immune system modulators also lead to immune-related adverse events (IRAEs).1,2 In clinical trials, IRAEs mainly involved the gastrointestinal tract, skin, endocrine glands, liver and lung,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences